EMA OKs Samsung BioLogics Biomanufacturing Facility
The European Medicines Agency (EMA) has licensed a 150,000-liter biomanufacturing facility of Samsung BioLogics, an Incheon, Korea-based contract biologics manufacturer. The plant, which was approved for monoclonal antibody production, was earlier approved in October 2017 by the US Food and Drug Administration.
The second approved biomanufacturing facility has 150,000 liters of production capacity and 10 bioreactors, which is five times larger than Samsung’s first biomanufacturing plant. Samsung BioLogics has invested $740 million in a third plant with bioreactor capacity of 180,000 liters in Incheon with construction completed in November 2017. The company’s third plant is expected to be operational in 2018 and would give Samsung BioLogics total production capacity of 362,000 liters.
Source: Samsung Biologics